What is MTD Micro Molding?
MTD Micro Molding operates as a specialized manufacturer dedicated to the production of minimally invasive medical devices. The company distinguishes itself through a vertically integrated service model that encompasses micro materials, precision part design, tooling, molding, and final assembly. By maintaining an FDA-registered and ISO 13485:2016-certified facility, the organization provides a reliable pathway for medical device companies to transition from prototype to validated, high-volume production.
Their core competency lies in the mastery of bioabsorbable materials and micro-scale engineering, which are essential for the next generation of healthtech innovation. By consolidating the entire development lifecycle under one roof, MTD Micro Molding effectively mitigates supply chain risks and accelerates time-to-market for its clients, positioning itself as a vital partner for firms navigating the complexities of modern medical device regulation.
How much funding has MTD Micro Molding raised?
MTD Micro Molding has raised a total of $988K across 2 funding rounds:
Debt
$350K
Debt
$638K
Debt (2020): $350K with participation from PPP
Debt (2021): $638K led by PPP
Key Investors in MTD Micro Molding
PPP
Public-Private Partnership
What's next for MTD Micro Molding?
With the recent influx of capital, MTD Micro Molding is well-positioned to enhance its manufacturing infrastructure and deepen its expertise in advanced material science. The strategic focus will likely shift toward increasing production capacity for bioabsorbable components, a segment experiencing significant demand due to the rise of minimally invasive surgical procedures. Furthermore, the company is expected to continue its commitment to rigorous quality standards, ensuring that its technological advancements remain aligned with evolving international medical device regulations.
As the healthtech landscape becomes increasingly reliant on miniaturized, high-precision components, MTD Micro Molding's ability to scale its proprietary processes will be a key driver of its long-term competitive advantage. The firm's ongoing investment in tooling and assembly automation suggests a roadmap focused on operational efficiency and the pursuit of complex, high-value manufacturing contracts within the global medical device ecosystem.
